CLOSE
Original image

Where Are They Now? Diseases That Killed You in Oregon Trail

Original image

You have died of dysentery.

These are five words familiar to anyone who has attempted to caulk a wagon and ford rivers en route to the Willamette Valley. Oregon Trail not only taught generations of kids about Western migration in 19th-century America, it also familiarized them with various strange-sounding diseases. Let’s catch up with some of those diseases and find out if they're just as nasty today.

1. Everyone Has Cholera

Then: The number one killer of the actual Oregon Trail, cholera is an infection of the intestines caused by ingesting the bacteria Vibrio cholerae. Spread through contaminated food or water, cholera released an enterotoxin that effectively flooded the intestines with excess water. This led to continual watery diarrhea, causing severe dehydration and often death. The worst outbreaks occurred on the Oregon Trail in 1849, 1850 and 1852. The only available treatment in the game was a medicine known as laudanum—understood today to be pure opium.

Now: According to the Centers for Disease Control, cholera remains a global pandemic. Though there is still no vaccine for the disease (in the U.S.), it can be treated with a regimen of fluids and electrolytes, as well as antibiotics. The best defense remains stringent sanitation regulations, a luxury afforded primarily to industrialized countries. The World Health Organization has recorded recent outbreaks in Mexico (November 2013), Sierra Leone (August 2012), Democratic Republic of Congo (July 2011), Haiti (November 2010, October 2010), Pakistan (October 2010) and a severe outbreak in Zimbabwe (June 2009, March 2009, February 2009, January 2009, December 2008).

2. Joseph Has Diphtheria

Then: Caused by Corynebacterium diphtheriae, diphtheria is an airborne bacterial disease. It usually showed up first in the nose and throat, but could also surface as skin lesions. A gray, fibrous material would grow over airways, causing difficulty breathing and sometimes uncontrollable drooling, as well as a deep cough and chills. Diphtheria was most common on the Trail during the winter months.

Now: Routine childhood immunizations have nearly erased diphtheria in the U.S. According to the U.S. National Library of Medicine, there are less than five cases here a year. Though it is still a problem in crowded nations with poor hygiene, diphtheria is now rarely fatal.

3. You Have Dysentery

Then: Dysentery, a.k.a. shigellosis, was not as widespread on the trails as its peer cholera. During the 19th century, dysentery was a bigger problem on the Civil War battlefields. Like cholera, dysentery spread via contaminated water and food, thriving in hot and humid weather. Unlike cholera, dysentery lived in the colon and caused bloody, loose excrement. The rise of dysentery in the 1800s was partially due to infected warm cow’s milk, an ideal incubator for shigellosis.

Now: Dysentery is still a major threat to the developing world. Not only is there no effective vaccine, recent strains are increasingly resistant to antibiotics—the only proven line of defense in tandem with fluids. 

4. Sally Has Measles

Then: Evolved from the rinderpest virus, the highly contagious measles ravaged the United States in the 19th century. It was not measles, but complications like bronchitis and pneumonia, that made it life threatening. Measles was spread through contaminated droplets—coughing, sneezing, wiping one’s nose and then touching anything. It caused nasty rashes, fever, and conjunctivitis.

Now: A vaccine was discovered in the mid-20th century, virtually eradicating measles from the developed world. It is now part of the trifecta inoculation MMR (Measles-Mumps-Rubella) most American children receive in infancy and again at age 6. Though relatively contained, measles is still endemic: In 2009, there was an outbreak in Johannesburg and other parts of South Africa. New Zealand saw a small spike in August 2011, with nearly 100 cases popping up in Auckland. And as of May 16, 2014, there have been 15 outbreaks in the U.S., resulting in 216 cases of measles in 18 states, "the highest number of cases reported in the United States during this time period in 18 years," Dr. Greg Wallace, head of measles activities at the Centers for Disease Control and Prevention, told CNN. (Notably, that number doesn't include the latest cases from an outbreak in Ohio.) Most of the people who got measles were unvaccinated and got the disease while traveling; measles then spread among unvaccinated members of the community when the travelers returned home.

5. Mary Has Died of Typhoid Fever

Then: Unfamiliar with the virtues of boiling water first, Oregon Trail pioneers contracted typhoid like many other diseases—from contaminated water. Caused by Salmonella Typhi, typhoid was spread when an infected person “sheds” the bacteria. Sparing you the gross details, let’s just say the bacteria lived in a person’s blood and intestines. The major symptom was high fever, followed by weakness and loss of appetite. In the warmer months, typhoid was a real killer.

Now: Still a killer, though not in the Western world. The CDC says it’s preventable with good sanitation and antibiotics, but even Westerners are not immune when traveling in developing countries. The CDC strongly recommends anyone planning travel to a "non-industrialized" nation get vaccinated—and avoid any tap water or food cooked in unclean water.

This story originally appeared in 2011.

Original image
iStock
arrow
Live Smarter
Beyond the Label: How to Pick the Right Medicines For Your Cold and Flu Symptoms
Original image
iStock

The average household spends an annual total of $338 on various over-the-counter medicines, with consumers making around 26 pharmacy runs each year, according to 2015 data from the Consumer Healthcare Products Association. To save cash and minimize effort (here's why you'd rather be sleeping), the Cleveland Clinic recommends avoiding certain cold and flu products, and selecting products containing specific active ingredients.

Since medicine labels can be confusing (lots of people likely can’t remember—let alone spell—words like cetirizine, benzocaine, or dextromethorphan), the famous hospital created an interactive infographic to help patients select the right product for them. Click on your symptom, and you’ll see ingredients that have been clinically proven to relieve runny or stuffy noses, fevers, aches, and coughs. Since every medicine is different, you’ll also receive safety tips regarding dosage levels, side effects, and the average duration of effectiveness.

Next time you get sick, keep an eye out for these suggested elements while comparing products at the pharmacy. In the meantime, a few pro tips: To avoid annoying side effects, steer clear of multi-symptom products if you think just one ingredient will do it for you. And while you’re at it, avoid nasal sprays with phenylephrine and cough syrups with guaifenesin, as experts say they may not actually work. Cold and flu season is always annoying—but it shouldn’t be expensive to boot.

Original image
ETH Zurich
arrow
Medicine
This Soft Artificial Heart May One Day Shorten the Heart Transplant List
Original image
ETH Zurich

If the heart in the Functional Materials Laboratory at ETH Zurich University were in a patient in an operating room, its vital signs would not be good. In fact, it would be in heart failure. Thankfully, it's not in a patient—and it's not even real. This heart is made of silicone.

Suspended in a metal frame and connected by tubes to trays of water standing in for blood, the silicone heart pumps water at a beat per second—a serious athlete's resting heart rate—in an approximation of the circulatory system. One valve is leaking, dripping onto the grate below, and the water bins are jerry-rigged with duct tape. If left to finish out its life to the final heartbeat, it would last for about 3000 beats before it ruptured. That's about 30 minutes—not long enough to finish an episode of Grey's Anatomy

Nicolas Cohrs, a bioengineering Ph.D. student from the university, admits that the artificial heart is usually in better shape. The one he holds in his hands—identical to the first—feels like taut but pliable muscle, and is intact and dry. He'd hoped to demonstrate a new and improved version of the heart, but that one is temporarily lost, likely hiding in a box somewhere at the airport in Tallinn, Estonia, where the researchers recently attended a symposium.

Taking place over the past three years, the experimental research is a part of Zurich Heart, a project involving 17 researchers from multiple institutions, including ETH, the University of Zurich, University Hospital of Zurich, and the German Heart Institute in Berlin, which has the largest artificial heart program in Europe.

A BRIDGE TO TRANSPLANT—OR TO DEATH

Heart failure occurs when the heart cannot pump enough blood and oxygen to support the organs; common causes are coronary heart disease, high blood pressure, and diabetes. It's a global pandemic, threatening 26 million people worldwide every year. More than a quarter of them are in the U.S. alone, and the numbers are rising.

It's a life-threatening disease, but depending on the severity of the condition at the time of diagnosis, it's not necessarily an immediate death sentence. About half of the people in the U.S. diagnosed with the disease die within five years. Right now in the U.S., there are nearly 4000 people on the national heart transplant list, but they're a select few; it's estimated that upwards of 100,000 people need a new heart. Worldwide, demand for a new heart greatly outpaces supply, and many people die waiting for one.

That's why Cohrs, co-researcher Anastasios Petrou, and their colleagues are attempting to create an artificial heart modeled after each patient's own heart that would, ideally, last for the rest of a person's life.

Mechanical assistance devices for failing hearts exist, but they have serious limitations. Doctors treating heart failure have two options: a pump placed next to the heart, generally on the left side, that pumps the blood for the heart (what's known as a left ventricular assist device, or LVAD), or a total artificial heart (TAH). There have been a few total artificial hearts over the years, and at least four others are in development right now in Europe and the U.S. But only one currently has FDA approval and CE marking (allowing its use in European Union countries): the SynCardia total artificial heart. It debuted in the early '90s, and since has been implanted in nearly 1600 people worldwide.

While all implants come with side effects, especially when the immune system grows hostile toward a foreign object in the body, a common problem with existing total artificial hearts is that they're composed of hard materials, which can cause blood to clot. Such clots can lead to thrombosis and strokes, so anyone with an artificial heart has to take anticoagulants. In fact, Cohrs tells Mental Floss, patients with some sort of artificial heart implant—either a LVAD or a TAH—die more frequently from a stroke or an infection than they do from the heart condition that led to the implant. Neurological damage and equipment breakdown are risky side effects as well.

These complications mean that total artificial hearts are "bridges"—either to a new heart, or to death. They're designed to extend the life of a critically ill patient long enough to get on (or to the top of) the heart transplant list, or, if they're not a candidate for transplant, to make the last few years of a person's life more functional. A Turkish patient currently holds the record for the longest time living with a SynCardia artificial heart: The implant has been in his chest for five years. Most TAH patients live at least one year, but survival rates drop off after that.

The ETH team set out to make an artificial heart that would be not a bridge, but a true replacement. "When we heard about these problems, we thought about how we can make an artificial heart that doesn't have side effects," he recalls.

USING AN ANCIENT TECHNIQUE TO MAKE A MODERN MARVEL

Using common computer assisted design (CAD) software, they designed an ersatz organ composed of soft material that hews closely to the composition, form, and function of the human heart. "Our working hypothesis is that when you have such a device which mimics the human heart in function and form, you will have less side effects," Cohrs says.

To create a heart, "we take a CT scan of a patient, then put it into a computer file and design the artificial heart around it in close resemblance to the patient's heart, so it always fits inside [the body]," Cohrs says.

But though it's modeled on a patient's heart and looks eerily like one, it's not identical to the real organ. For one thing, it can't move on its own, so the team had to make some modifications. They omitted the upper chambers, called atria, which collect and store blood, but included the lower chambers, called ventricles, which pump blood. In a real heart, the left and right sides are separated by the septum. Here, the team replaced the septum with an expansion chamber that is inflated and deflated with pressurized air. This action mimics heart muscle contractions that push blood from the heart.

The next step was to 3D-print a negative mold of the heart in ABS, a thermoplastic commonly used in 3D printing. It takes about 40 hours on the older-model 3D printers they have in the lab. They then filled this mold with the "heart" material—initially silicone—and let it cure for 36 hours, first at room temperature and then in an oven kept at a low temperature (about 150°F). The next day, they bathed it in a solvent of acetone, which dissolved the mold but left the printed heart alone. This process is essentially lost-wax casting, a technique used virtually unchanged for the past 4000 years to make metal objects, especially bronze. It takes about four days.

The resulting soft heart weighs about 13 ounces—about one-third more than an average adult heart (about 10 ounces). If implanted in a body, it would be sutured to the valves, arteries, and veins that bring blood through the body. Like existing ventricular assist devices and total artificial hearts on the market, it would be powered by a portable pneumatic driver worn externally by the patient.

FROM 3000 TO 1 MILLION HEARTBEATS

In April 2016, they did a feasibility test to see if their silicone organ could pump blood like a real heart. First they incorporated state-of-the-art artificial valves used every day in heart surgeries around the world. These would direct the flow of blood. Then, collaborating with a team of mechanical engineers from ETH, they placed the heart in a hybrid mock circulation machine, which measures and simulates the human cardiovascular system. "You can really measure the relevant data without having to put your heart into an animal," says Cohrs.

Here's what the test looked like.

"Our results were very nice," Cohrs says. "When you look at the pressure waveform in the aorta, it really looked like the pressure waveform from the human heart, so that blood flow is very comparable to the blood flow from a real human heart."

Their results were published earlier this year in the journal Artificial Organs.

But less promising was the number of heartbeats the heart lasted before rupturing under stress. (On repeated tests, the heart always ruptured in the same place: a weak point between the expansion chamber and the left ventricle where the membrane was apparently too thin.) With the average human heart beating 2.5 billion times in a lifetime, 3000 heartbeats wouldn't get a patient far.

But they're making progress. Since then, they've switched the heart material from silicone to a high-tech polymer. The latest version of the heart—one of which was stuck in that box in the Tallinn airport—lasts for 1 million heartbeats. That's an exponential increase from 3000—but it's still only about 10 days' worth of life.

Right now, the heart costs around $400 USD to produce, "but when you want to do it under conditions where you can manufacture a device where it can be implanted into a body, it will be much more expensive," Cohrs says.

The researchers know they're far from having produced an implantable TAH; this soft heart represents a new concept for future artificial heart development that could one day lead to transplant centers using widely available, easy-to-use design software and commercially available 3D-printers to create a personalized heart for each patient. This kind of artificial heart would be not a bridge to transplantation or, in a few short years, death, but one that would take a person through many years of life.

"My personal goal is to have an artificial heart where you don't have side effects and you don't have any heart problems anymore, so it would last pretty much forever," Cohrs says. Well, perhaps not forever: "An artificial heart valve last 15 years at the moment. Maybe something like that."

SECTIONS

arrow
LIVE SMARTER
More from mental floss studios